QuidelOrtho price to book ratio QDEL
Market value divided by the book value of the company's net assets, since 2022.
- Today, Oct 23, 2026
- 0.5×
- 4-year median
- 0.9×
- Against its 4-year history
- 10th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.4× to 1.3×
- Peer median
- 8.9×
QuidelOrtho's price to book ratio is 0.5× as of Oct 23, 2026.
That is below its 4-year median of 0.9×, lower than on 90% of days in the last 4 years.
Over that time it ranged from 0.4× in May 2026 to 1.3× in Dec 2022.
The median for 6 diagnostics and research stocks of a similar size is 8.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.5× | 0.4× | 1.1× |
| 2025 | 1.0× | 0.5× | 1.0× |
| 2024 | 0.9× | 0.5× | 1.0× |
| 2023 | 1.0× | 0.8× | 1.3× |
| 2022 | 1.2× | 1.0× | 1.3× |
Against its peers
Companies in Medical - Diagnostics & Research nearest QuidelOrtho's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| QDELQuidelOrtho | 0.5× |
| NRCNRC Health | 74.1× |
| CDNACareDx | 8.4× |
| VCYTVeracyte | 2.8× |
| BLLNBillionToOne | 9.5× |
| LNTHLantheus | 5.0× |
| CAICaris Life Sciences | 15.3× |
| Peer median | 8.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on QuidelOrtho
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.